Abingworth announces leadership transition and appointments

Abingworth, a transatlantic life sciences investment firm and part of global investment firm Carlyle (Nasdaq: CG), today announced several leadership changes.

Kurt von Emster, managing partner and head of Abingworth Life Sciences, is transitioning to managing partner of Abingworth. Dr Bali Muralidhar, managing partner, chief investment officer, and chief operating officer of Abingworth, has been appointed Head of Abingworth Life Sciences and CIO. Travis Wilson has also joined as managing director across Abingworth and Carlyle, focusing on clinical co-development and biotech and pharma buyout opportunities, further strengthening Carlyle’s life sciences franchise.

Mr von Emster said: “After eleven years leading Abingworth, including the firm’s expansion into clinical co-development and strategic relationship with Carlyle, Abingworth is now in an excellent place to continue its success as a leader in life sciences investing. I have worked closely with Dr Bali Muralidhar for the past seven years, and he has demonstrated the vision and leadership to continue Abingworth’s 53 years of successful life sciences investing. I believe his leadership as Head of Abingworth Life Sciences will benefit our investors, the Abingworth team, and the continued evolution of our best-in-class transatlantic life sciences investing platform.”